Logo

• Finished gynecological cancer (KGOG3044)

  A phase II trial to evaluate the efficacy of Bortezomib and Pegylated liposomal doxorubicin in patients with BRCA wild-type platinum-resistant recurrent ovarian cancer

  • PI / PI기관 Kidong Kim /
  • Registration Date / Last Update Posted 2022-05-10 / 2023-03-28
  • Current Enrollment / Estimated Enrollment 23 person / 44 person (52.300000000000004%)

• Finished gynecological cancer (KGOG3043)

  EAE 161: Perfusion CT to Predict Progression-free Survival and Response Rate in Bevacizumab and Paclitaxel Treatment of Platinum-Resistant Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Peritoneal Carcinoma

  • PI / PI기관 Hyun Hoon Chung /
  • Registration Date / Last Update Posted 2022-05-10 / 2023-07-06
  • Current Enrollment / Estimated Enrollment 3 person / 300 person (1.0%)

• Finished gynecological cancer (KGOG3037)

  NRG-GY005: A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)

  • PI / PI기관 Yong Man Kim /
  • Registration Date / Last Update Posted 2022-05-10 / 2023-03-28
  • Current Enrollment / Estimated Enrollment 562 person / 570 person (98.6%)

• Finished gynecological cancer (KGOG3034R)

  Retrospective-SOTO study: Searching an Optimal Third line chemotherapy in Ovarian cancer

  • PI / PI기관 Sang Wun Kim /
  • Registration Date / Last Update Posted 2022-05-10 / 2023-03-28
  • Current Enrollment / Estimated Enrollment 725 person / 400 person (181.29999999999998%)

• Finished gynecological cancer (KGOG3032)

  Prevalence Study of Germline and/or Somatic BRCA1/2 Mutation in Korean Patients with High-Grade Serous and/or Endometrioid Epithelial Ovarian, Fallopian tube, or Primary Peritoneal Cancer

  • PI / PI기관 Byoung-Gie Kim /
  • Registration Date / Last Update Posted 2022-05-10 / 2023-03-28
  • Current Enrollment / Estimated Enrollment 0 person / 300 person (0.0%)

• Finished gynecological cancer (KGOG3030)

  A randomized phase 1 trial evaluating the safety of weekly Paclitaxel with Oncothermia and weekly cisPlatin with Oncothermia in Patients with recurrent or persistent epithelial Ovarian, fallopian tube or primary peritoneal carcinoma (POPOPO trial)

  • PI / PI기관 Yong Beom Kim /
  • Registration Date / Last Update Posted 2022-05-10 / 2023-03-28
  • Current Enrollment / Estimated Enrollment 7 person / 12 person (58.3%)

• Finished gynecological cancer (KGOG3028)

  Retrospective-Laparoscopic Surgery in Epithelial Ovarian Cancer

  • PI / PI기관 Joo-Hyun Nam /
  • Registration Date / Last Update Posted 2022-05-10 / 2023-03-28
  • Current Enrollment / Estimated Enrollment 1342 person / 800 person (167.79999999999998%)

• Finished gynecological cancer (KGOG3025)

  GOG-268: A phase II evaluation of temsirolimus (CCI-779) (NCI supplied agent: NSC# 683864, IND# 61010) in combination with carboplatin and paclitaxel followed by temsirolimus (CCI-779) consolidation as first-line therapy in the treatment of stage III-IV clear cell carcinoma of the ovary

  • PI / PI기관 Tae-Joong Kim /
  • Registration Date / Last Update Posted 2022-05-10 / 2023-03-28
  • Current Enrollment / Estimated Enrollment 95 person / 90 person (105.60000000000001%)

• Finished gynecological cancer (KGOG3024)

  GOG-254: A phase II evaluation of su11248 (sunitinib malate) (IND #74019, NSC#736511) in the treatment of persistent or recurrent clear cell ovarian carcinoma

  • PI / PI기관 Jeong Yeol Park /
  • Registration Date / Last Update Posted 2022-05-10 / 2023-03-28
  • Current Enrollment / Estimated Enrollment 38 person / 34 person (111.79999999999998%)

• Finished gynecological cancer (KGOG3023)

  GOG-262 :A Randomized Phase III Trial of Dose Dense Weekly Paclitaxel Combined with Carboplatin Versus Dose Dense Weekly Paclitaxel Plus Bevacizumab (NSC #704865, IND #7921), Combined with Carboplatin Versus Every-3-Weeks Paclitaxel Plus Bevacizumab (NSC #704865, IND #7921) Combined with Carboplatin in the Treatment of Primary Stage III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer

  • PI / PI기관 Yong Man Kim /
  • Registration Date / Last Update Posted 2022-05-10 / 2023-03-28
  • Current Enrollment / Estimated Enrollment 841 person / 841 person (100.0%)

* (사)대한부인종양연구회는 게시된 세부 임상연구 정보에 대해 법적 책임이 없습니다.